Medical Technology

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 years ago

Two Days, Six IPOs, and $1B Raised for Biotech Research & More

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 3 years ago

CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

@xconomy.com 3 years ago

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

@xconomy.com 3 years ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 years ago

Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14

@xconomy.com 4 years ago

Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone